Subtype
Colon Neoplasm
CI-CAN-00004992Explore in graph →
Non-malignant271 active trials5 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004992Explore in graph →
Clinical trials
1,560 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04259944 | Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | unknown | Phase 2 | 140 | IFOM ETS - The AIRC Institute of Molecular OncologyOTHER | 2 | Sep 28, 2023 |
| clinicaltrials |
| NCT06017141 | Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study | unknown | Phase 2 | 80 | University of Kansas Medical CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04798612 | Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression(IPOS) | unknown | Phase 2 | 68 | Zealand University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05914389 | Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer(ICONIC) | recruiting | Phase 2 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | terminated | Phase 1 / Phase 2 | 82 | Eisai Inc.INDUSTRY | 6 | Jun 22, 2023 | clinicaltrials |
| NCT03428126 | Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04189055 | Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.(CETIDYL) | unknown | Phase 2 | 72 | Hôpital Franco-Britannique-Fondation Cognacq-JayOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05833672 | Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers | unknown | Phase 2 | 100 | fan liOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05278351 | Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC | unknown | Phase 2 | 87 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT03801915 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05732493 | Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)(TORCH-C) | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 0 | Feb 17, 2023 | clinicaltrials |
| NCT03883802 | Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer(NeoFox) | unknown | Phase 2 | 100 | WntResearch ABINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05178576 | A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy | withdrawn | Phase 2 | 0 | NSABP Foundation IncNETWORK | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05433402 | Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sadat City UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | terminated | Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT05279677 | FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03524820 | Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer | terminated | Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05468177 | Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer(CIFOXRC) | unknown | Phase 2 | 66 | Tongji HospitalOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03086538 | Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy | completed | Phase 2 | 29 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03332498 | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | completed | Phase 1 / Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma(RENACOL) | withdrawn | Phase 1 / Phase 2 | 0 | Faron Pharmaceuticals LtdINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT05335460 | To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer | unknown | Phase 2 | 36 | Fujian Cancer HospitalOTHER_GOV | 0 | Apr 19, 2022 | clinicaltrials |
| NCT05299411 | Intravenous Iron Infusion on Chemotherapy-induced Anemia | unknown | Phase 2 | 80 | Korea University Guro HospitalOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT03359681 | Metformin Treatment for Colon Cancer(MECORA) | completed | Phase 2 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04167436 | Fit for Surgery. Multimodal Prehabilitation in Colorectal Cancer Patients | unknown | Phase 2 / Phase 3 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT05231850 | A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI. | not yet recruiting | Phase 2 | 70 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Feb 9, 2022 | clinicaltrials |
| NCT00193219 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 36 | SCRI Development Innovations, LLCOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03661047 | OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer(OMICC) | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Nov 17, 2021 | clinicaltrials |
| NCT04296019 | Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | unknown | Phase 2 | 110 | Shanghai Zhongshan HospitalOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT01505166 | Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases(FANG-CLM) | terminated | Phase 2 | 3 | Gradalis, Inc.INDUSTRY | 1 | Nov 1, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT04969029 | Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT01902953 | Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) | completed | Phase 2 | 16 | Maimonides Medical CenterOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT00932438 | Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab(DEBIRI) | completed | Phase 1 / Phase 2 | 70 | University of LouisvilleOTHER | 2 | Jun 11, 2021 | clinicaltrials |
| NCT03484195 | Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer | unknown | Phase 2 | 30 | China Medical University, ChinaOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03329664 | Autologous Killer Cell Therapy in Colon Cancer Patients | unknown | Phase 1 / Phase 2 | 20 | Sabz BiomedicalsINDUSTRY | 1 | Mar 15, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT04775862 | A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer. | unknown | Phase 2 | 60 | National Guard Health AffairsOTHER_GOV | 1 | Mar 1, 2021 | clinicaltrials |
| NCT04737213 | SGM-101 in Colorectal Lung Metastases(SGM-CLM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03985891 | The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer(JSFOL) | unknown | Phase 1 / Phase 2 | 40 | Xiangya Hospital of Central South UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT01681472 | PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer | completed | Phase 1 / Phase 2 | 32 | Isofol Medical ABINDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT00192114 | Enzastaurin for Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 6, 2020 | clinicaltrials |
| NCT04475159 | Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial | unknown | Phase 2 | 50 | Prof. Aviram NissanOTHER_GOV | 0 | Jul 17, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Oct 17, 2023source: clinicaltrials